Shots:
- The P-III (QUANTI CNS) trial assessed GBCA gadoquatrane (0.04mmol Gd/kg) vs macrocyclic GBCAs (0.1mmol Gd/kg) in adults (n=305) with confirmed or suspected CNS pathologies undergoing contrast-enhanced MRI
- Study showed non-inferiority (1EP) & superiority across all visualization criteria (contrast enhancement, delineation, & morphology), plus higher sensitivity & specificity (2EP) for lesion detection & exclusion
- QUANTI program incl. 2 P-III trials: QUANTI CNS & QUANTI OBR (other body regions) for adults as well as QUANTI PEDIATRIC study in pts (birth to 18yrs.) for other body regions. Data of QUANTI OBR & QUANTI PEDIATRIC to be presented in future meetings with global regulatory filings underway
Ref: Bayer | Image: Bayer
Related News:- Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
